Document Detail

Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
MedLine Citation:
PMID:  17012299     Owner:  NLM     Status:  MEDLINE    
AIMS: HMG-CoA reductase inhibitors (statins) reduce cardiovascular mortality and morbidity in patients with stable coronary artery disease as well as acute coronary syndrome (ACS). It is unclear how rapidly the beneficial effects of statins occur in patients with ACS and whether these drug properties are related to lipid lowering. METHODS AND RESULTS: Patients with troponin-positive ACS (n=35) were randomized to 20 mg/day rosuvastatin therapy or to placebo treatment. Anti-inflammatory effects of rosuvastatin measured by lymphocyte intracellular cytokine production were taken before initiation of treatment and on days 1, 3, and 42. Compared with placebo, rosuvastatin treatment significantly reduced plasma concentrations of pro-inflammatory cytokines TNF-alpha and IFN-gamma at 72 h. Rosuvastatin also induced a rapid and significant reduction of TNF-alpha and IFN-gamma production in stimulated T-lymphocytes at 72 h. When compared with placebo, rosuvastatin inhibited the Th-1-immune response measured at 72 h. CONCLUSION: Rosuvastatin exerts rapid immunomodulatory effects on the level of T-cell activation in patients with ACS.
Andreas Link; Tarek Ayadhi; Michael Böhm; Georg Nickenig
Related Documents :
16282749 - Activation markers in behçet's disease.
16539279 - Circulating levels of beta2-glycoprotein i in thrombotic disorders and in inflammation.
15499539 - Activation of the cytokine network and unfavorable outcome in patients with yellow fever.
20618689 - Cytokine profiles of bronchoalveolar lavage fluid in patients with pneumocystis pneumonia.
18784579 - Correlation between il-6 levels and the systemic inflammatory response score: can an il...
12694249 - Mediators of inflammation correlate with microalbuminuria in patients with non-hodgkin'...
8318389 - Claudication in the setting of plethysmographic criteria for resting ischemia: is surge...
2311979 - Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic pat...
19021599 - Anti-aquaporin-4 antibody-positive optic neuritis.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-09-29
Journal Detail:
Title:  European heart journal     Volume:  27     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-05     Completed Date:  2007-04-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  2945-55     Citation Subset:  IM    
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, D-66421Homburg/Saar, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
C-Reactive Protein / metabolism
Coronary Artery Disease / drug therapy*
Cytokines / metabolism
Double-Blind Method
Fluorobenzenes / therapeutic use*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Immunologic Factors / therapeutic use*
Lipids / blood
Middle Aged
Monocytes / metabolism
Myocardial Ischemia / drug therapy*
Pyrimidines / therapeutic use*
Sulfonamides / therapeutic use*
T-Lymphocytes / metabolism
Reg. No./Substance:
0/Cytokines; 0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Immunologic Factors; 0/Lipids; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin; 9007-41-4/C-Reactive Protein
Comment In:
Eur Heart J. 2006 Dec;27(24):2916-8   [PMID:  17098759 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology.
Next Document:  Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.